Milestone Pharmaceuticals Inc (MIST) - Total Liabilities
Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has total liabilities worth $67.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MIST operating cash flow to assess how effectively this company generates cash.
Milestone Pharmaceuticals Inc - Total Liabilities Trend (2017–2024)
This chart illustrates how Milestone Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Milestone Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Milestone Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GPT Infraprojects Limited
NSE:GPTINFRA
|
India | Rs5.22 Billion |
|
Pro-Dex Inc
NASDAQ:PDEX
|
USA | $20.62 Million |
|
Intai Technology
TWO:4163
|
Taiwan | NT$2.08 Billion |
|
EKOS
IS:EKOS
|
Turkey | TL1.10 Billion |
|
BingEx Ltd
NASDAQ:FLX
|
USA | $432.60 Million |
|
Roularta
BR:ROU
|
Belgium | €134.09 Million |
|
ABOV Semiconductor Co. Ltd
KQ:102120
|
Korea | ₩132.48 Billion |
|
Southern Petrochemicals Industries Corporation Limited
NSE:SPIC
|
India | Rs9.37 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Milestone Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MIST company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Milestone Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual total liabilities of Milestone Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $62.35 Million | +6.67% |
| 2023-12-31 | $58.45 Million | +618.56% |
| 2022-12-31 | $8.13 Million | +12.22% |
| 2021-12-31 | $7.25 Million | +5.75% |
| 2020-12-31 | $6.86 Million | -19.46% |
| 2019-12-31 | $8.51 Million | -94.06% |
| 2018-12-31 | $143.29 Million | +136.03% |
| 2017-12-31 | $60.71 Million | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more